CTLA4 and acute myeloid leukemia: Although immune checkpoint blockade in AML has not proven beneficial, [136,137,138] there may still be additional effects in combining CAR T cells and immune checkpoint blockage (PD-1, CTLA-4, etc.)that will improve T cell persistence and anti-tumor efficacy [47].